These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 30455380)

  • 1. Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab.
    Langerak AW; Ritgen M; Goede V; Robrecht S; Bahlo J; Fischer K; Steurer M; Trněný M; Mulligan SP; Mey UJM; Trunzer K; Fingerle-Rowson G; Humphrey K; Stilgenbauer S; Böttcher S; Brüggemann M; Hallek M; Kneba M; van Dongen JJM
    Blood; 2019 Jan; 133(5):494-497. PubMed ID: 30455380
    [No Abstract]   [Full Text] [Related]  

  • 2. Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia.
    Seiter K; Mamorska-Dyga A
    Clin Interv Aging; 2015; 10():951-61. PubMed ID: 26109852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
    Goede V; Fischer K; Busch R; Engelke A; Eichhorst B; Wendtner CM; Chagorova T; de la Serna J; Dilhuydy MS; Illmer T; Opat S; Owen CJ; Samoylova O; Kreuzer KA; Stilgenbauer S; Döhner H; Langerak AW; Ritgen M; Kneba M; Asikanius E; Humphrey K; Wenger M; Hallek M
    N Engl J Med; 2014 Mar; 370(12):1101-10. PubMed ID: 24401022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO-CLLEAR Study by the Czech CLL Study Group.
    Panovská A; Němcová L; Nekvindová L; Špaček M; Šimkovič M; Papajík T; Brejcha M; Lysák D; Zuchnická J; Novák J; Starostka D; Poul H; Vrbacký F; Vodárek P; Urbanová R; Plevová K; Pospíšilová Š; Mašlejová S; Brychtová Y; Koriťáková E; Smolej L; Doubek M
    Hematol Oncol; 2020 Oct; 38(4):509-516. PubMed ID: 32400885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obinutuzumab: a novel anti-CD20 monoclonal antibody for previously untreated chronic lymphocytic leukemia.
    Shah A
    Ann Pharmacother; 2014 Oct; 48(10):1356-61. PubMed ID: 25037849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
    Cramer P; von Tresckow J; Eichhorst B; Hallek M
    Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of patients with previously untreated chronic lymphocytic leukaemia with obinutuzumab and chlorambucil.
    Tam C; Kuss B; Opat S; Boulos J; Marlton P
    Intern Med J; 2017 Jul; 47 Suppl 4():5-10. PubMed ID: 28685928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of obinutuzumab in the treatment of chronic lymphocytic leukemia.
    Jean GW; Comeau JM
    Am J Health Syst Pharm; 2015 Jun; 72(11):933-42. PubMed ID: 25987688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obinutuzumab for the treatment of chronic lymphocytic leukemia.
    Rogers KA; Jones JA
    Drugs Today (Barc); 2014 Jun; 50(6):407-19. PubMed ID: 24983589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obinutuzumab looks impressive in CLL.
    Cancer Discov; 2014 Apr; 4(4):OF5. PubMed ID: 24706674
    [No Abstract]   [Full Text] [Related]  

  • 11. Highlights in chronic lymphocytic leukemia from the 60th American Society of Hematology Annual Meeting.
    Clin Adv Hematol Oncol; 2019 Jan; 17 Suppl 1(1):1-24. PubMed ID: 31545307
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and safety of the obinutuzumab-chlorambucil combination in the frontline treatment of elderly CLL patients with comorbidities - Polish Adult Leukemia Group (PALG) real-life analysis.
    Długosz-Danecka M; Jurczak W; Łątka-Cabała E; Morawska M; Gawroński K; Wiśniewska A; Dudziński M; Wąsik-Szczepanek E; Chmielowska E; Łabędź A; Wdowiak K; Hus I
    Pol Arch Intern Med; 2018 Aug; 128(7-8):421-426. PubMed ID: 30057377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obinutuzumab (Gazyva) for chronic lymphocytic leukemia.
    Med Lett Drugs Ther; 2014 Nov; 56(1455):e114-5. PubMed ID: 25538980
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands.
    Blommestein HM; de Groot S; Aarts MJ; Vemer P; de Vries R; van Abeelen AF; Posthuma EF; Uyl-de Groot CA
    Leuk Res; 2016 Nov; 50():37-45. PubMed ID: 27657652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obinutuzumab for chronic lymphocytic leukemia.
    Rioufol C; Salles G
    Expert Rev Hematol; 2014 Oct; 7(5):533-43. PubMed ID: 25163491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
    Moreno C; Greil R; Demirkan F; Tedeschi A; Anz B; Larratt L; Simkovic M; Samoilova O; Novak J; Ben-Yehuda D; Strugov V; Gill D; Gribben JG; Hsu E; Lih CJ; Zhou C; Clow F; James DF; Styles L; Flinn IW
    Lancet Oncol; 2019 Jan; 20(1):43-56. PubMed ID: 30522969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?
    Van Den Neste E; Letestu R; Aurran-Schleinitz T; Ysebaert L; Feugier P; Leprêtre S; Dartigeas C
    Leuk Lymphoma; 2012 Mar; 53(3):362-70. PubMed ID: 21854093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification.
    Laurenti L; Innocenti I; Autore F; Ciolli S; Mauro FR; Mannina D; Del Poeta G; D'Arena G; Massaia M; Coscia M; Molica S; Pozzato G; Efremov DG; Vannata B; Marasca R; Galieni P; Cuneo A; Orlando S; Piciocchi A; Boncompagni R; Vincelli D; Liberati AM; Russo F; Foá R
    Haematologica; 2017 Sep; 102(9):e352-e355. PubMed ID: 28596282
    [No Abstract]   [Full Text] [Related]  

  • 19. Obinutuzumab: a review of its use in patients with chronic lymphocytic leukaemia.
    Hoy SM
    Drugs; 2015 Feb; 75(3):285-96. PubMed ID: 25586272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obinutuzumab Plus Chlorambucil in a Patient with Severe Myasthenia Gravis and Chronic Lymphocytic Leukemia.
    Russell A; Yaraskavitch M; Fok D; Chhibber S; Street L; Korngut L
    J Neuromuscul Dis; 2017; 4(3):251-257. PubMed ID: 28869483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.